“Forced out? No, …” Agreed…Dr. J is cer
Post# of 148110
(Total Views: 1550)
Posted On: 05/24/2024 11:25:15 AM
“Forced out? No, …”
Agreed…Dr. J is certainly not being forced out of Quest Clinical Research. If what I think is happening comes to pass it is intentional on his part and part of a higher good. As I have previously mentioned, this is very likely not about money and if you want to spend an hour with this man you can sense his motivations by listening to the linked video below. Regarding money, I think Dr Jay understands Leronlimab’s potential as a platform drug. Merck’s darling Keytruda pulled down $25 billion last year, yet the PD-1 blocker touches some cancers not at all and is speaking to 15% of the cancer audience. In the case of colorectal cancer micro satellite stable population, 85% are out of luck. A fully trialed Leronlimab as an adjunctive treatment for even the subset affected by PD-1 inhibitors if successful…well, my shorthand back of envelope for our hero Leronlimab assuming 85% would mean $167 billion in annual revenue. This is to say nothing of the potential contributions from long covid, MASH etc.
But enough of money…if Jay is 65, he is not looking for a get rich quick scheme…he came on board at Cytodyn with minimum salary. He is a healer first. His father was the prime impulse behind modern immunology and Jay is following in his footsteps. Under Quest he has been the principal investigator on 300 studies, viral and cancer related and he has a deep understanding of immunology and how it plays out in these clinical areas.
In the interview when asked to describe himself he said number one he thinks about himself as a patient advocate…medical director of Quest and his involvement with Cytodyn and Virion back in 2020 were down the list. At 65 you are probably thinking more about legacy and contribution to humanity, not money. This is a touching thoughtful interview; in Jay’s generous offering of time with a bunch of kids he said (in the midst of the COVID pandemic in 2020) this was his third holocaust…his mother survived the holocaust, he was in SF in the trenches at the height of the HIV pandemic, then comes Covid. You don’t live through a holocaust as a physician without an enduring impulse to help humanity survive the tidal wave of suffering, that is what he did at Quest and that is what he is about to do in his tenure at Cytodyn.
I am clear on the notion Jay as a “patient advocate first” wants this drug in the hands of doctors who are struggling with myriad clinical conditions where he knows as an immunologist it can make a difference. At 65 I don’t suspect he will take the long road to get it done either. Collaboration and partnership are the key words here where the underlying goal is accelerated path to APPROVAL.
https://m.youtube.com/watch?v=lw7jnA0sQRM
Agreed…Dr. J is certainly not being forced out of Quest Clinical Research. If what I think is happening comes to pass it is intentional on his part and part of a higher good. As I have previously mentioned, this is very likely not about money and if you want to spend an hour with this man you can sense his motivations by listening to the linked video below. Regarding money, I think Dr Jay understands Leronlimab’s potential as a platform drug. Merck’s darling Keytruda pulled down $25 billion last year, yet the PD-1 blocker touches some cancers not at all and is speaking to 15% of the cancer audience. In the case of colorectal cancer micro satellite stable population, 85% are out of luck. A fully trialed Leronlimab as an adjunctive treatment for even the subset affected by PD-1 inhibitors if successful…well, my shorthand back of envelope for our hero Leronlimab assuming 85% would mean $167 billion in annual revenue. This is to say nothing of the potential contributions from long covid, MASH etc.
But enough of money…if Jay is 65, he is not looking for a get rich quick scheme…he came on board at Cytodyn with minimum salary. He is a healer first. His father was the prime impulse behind modern immunology and Jay is following in his footsteps. Under Quest he has been the principal investigator on 300 studies, viral and cancer related and he has a deep understanding of immunology and how it plays out in these clinical areas.
In the interview when asked to describe himself he said number one he thinks about himself as a patient advocate…medical director of Quest and his involvement with Cytodyn and Virion back in 2020 were down the list. At 65 you are probably thinking more about legacy and contribution to humanity, not money. This is a touching thoughtful interview; in Jay’s generous offering of time with a bunch of kids he said (in the midst of the COVID pandemic in 2020) this was his third holocaust…his mother survived the holocaust, he was in SF in the trenches at the height of the HIV pandemic, then comes Covid. You don’t live through a holocaust as a physician without an enduring impulse to help humanity survive the tidal wave of suffering, that is what he did at Quest and that is what he is about to do in his tenure at Cytodyn.
I am clear on the notion Jay as a “patient advocate first” wants this drug in the hands of doctors who are struggling with myriad clinical conditions where he knows as an immunologist it can make a difference. At 65 I don’t suspect he will take the long road to get it done either. Collaboration and partnership are the key words here where the underlying goal is accelerated path to APPROVAL.
https://m.youtube.com/watch?v=lw7jnA0sQRM
(25)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼